Legal Representation
Attorney
TRACY-GENE G. DURKIN
USPTO Deadlines
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 19, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 19, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jan 16, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 16, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jul 12, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jul 12, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jul 12, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 27, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 27, 2024 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Feb 26, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 26, 2024 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Feb 5, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 18, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 18, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 18, 2024 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Jan 18, 2024 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Jul 15, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 13, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 13, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jul 13, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 20, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 18, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 18, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 19, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 24, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 24, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 4, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 20, 2022 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Apr 20, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 13, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 13, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 12, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 7, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 6, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Apr 6, 2022 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Apr 6, 2022 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Apr 6, 2022 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Oct 6, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 6, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 6, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 6, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 5, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 5, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 6, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 2, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 6, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the prevention of cancer and tumors; pharmaceutical preparations for use in the prevention of infectious, oncological, inflammatory, immune, autoimmune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and biological preparations in the nature of pharmaceutical and biological preparations for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, autoimmune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans
Additional Information
Design Mark
The mark consists of the letters "ADC" above the word "THERAPEUTICS". The letters "ADC" are in darker and lighter shades of blue. An orange wave element extends across the letter "A" to a shared edge of the letters "D" and "C". The word "THERAPEUTICS" is orange.
Color Claim
The color(s) blue and orange is/are claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"